UK markets closed

Emergent BioSolutions Inc. (0IGA.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
2.0600-0.1550 (-7.00%)
At close: 06:45PM BST
Full screen
Previous close2.2150
Bid0.0000 x N/A
Ask0.0000 x N/A
Day's range2.0600 - 2.1600
52-week range1.4800 - 13.4182
Avg. volume19,429
Market cap909,658
Beta (5Y monthly)1.19
PE ratio (TTM)0.01
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Aquestive Therapeutics Strengthens Board of Directors with Experienced Biotech Executive

    Appoints Abigail “Abbey” Jenkins, a veteran biotech executive with over 20 years of experience in commercial leadership, to Board of DirectorsWARREN, N.J., April 01, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the appointment of Abigail Jenkins to the Company’s Board of Direct

  • GlobeNewswire

    Emergent BioSolutions Continues to Broaden Access, Awareness and Availability of NARCAN® Nasal Spray to Help Save Lives from the Ongoing Opioid Crisis

    As the first-ever U.S. Food and Drug Administration (FDA) approved over-the-counter (OTC) naloxone in 2023, Emergent is working to expand access with NARCAN® Nasal Spray and build on its longstanding efforts with public interest entities across the country Hundreds of thousands of NARCAN® Nasal Spray cartons are available in over 32,000 retail locations in the U.S., and Emergent is working to increase reach into workplaces, businesses and other locationsApproximately 22 million doses of NARCAN®

  • GlobeNewswire

    Emergent BioSolutions Receives NAI Status for Baltimore Bayview Manufacturing Facility

    GAITHERSBURG, Md., March 25, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced that the U.S. Food and Drug Administration (FDA) has listed “No Action Indicated” or NAI status classification for the company's Baltimore Bayview manufacturing facility. Based on this outcome, the Baltimore Bayview facility is considered to be in an acceptable state of compliance with regard to current good manufacturing practices (cGMP). “Quality and compliance excellence remains a top priori